[ad_1]
Since its preliminary funding final yr, Protai has launched collaborations with main hospitals, opened a moist lab and expanded its advisory board with world-renowned oncology consultants, together with MD Anderson’s CSO, Prof. Giulio Draetta
Protai, a proteomics and AI-powered drug discovery startup revolutionizing the way in which new medicine are found, right now introduced that it has added $12 million to its seed spherical, bringing the full quantity to $20M. The spherical contains present buyers Grove Ventures and Pitango HealthTech and was joined by Copenhagen-based Maj Invest Equity Fund. The extra funding will probably be used to construct Protai’s oncology drug discovery pipeline, develop information acquisition in addition to enhance its discovery actions by way of pharma partnerships.
Genomic biomarkers are solely related for about 15% of tumors, thus restricted in use. Protein-level biomarkers can predict affected person populations not seen by genomic means, by instantly measuring proteins, their interactions, and their capabilities. To faucet into the potential of protein-level information, Protai has constructed a proteomics AI-based platform that comprehensively maps the course of a illness on the protein degree. Its know-how permits it to raised predict which sufferers will reply to a given drug, in addition to uncover novel drug targets that had been missed by genomic approaches. These discoveries will be the key to considerably accelerating drug discovery and medical improvement, reducing the time and prices of R&D.
Since its preliminary funding final yr, Protai has opened laboratories at its Israel R&D middle for information acquisition, organic validation and drug discovery actions and recruited an skilled drug discovery staff with vital expertise in efficiently bringing medicine to the clinic. Moreover, Protai established collaborations with a number of main hospitals, and now has entry to over 100k well-defined banked samples for its complete tumor mapping course of, centered on gyno-oncology and lung most cancers indications.
With the extra funding, Protai will develop its actions to incorporate an oncology drug discovery pipeline, initially specializing in targets with a clearly-defined novel affected person inhabitants biomarker, derived from its AI proteomics platform. To assist navigate these efforts, the corporate has added Dr. Sharon Shacham, a serial biotech entrepreneur and Founding father of Karyopharm Therapeutics, to Protai’s Board of Administrators. As well as, Protai is supported by main oncology consultants, together with Prof. Giulio Draetta, Chief Scientific Officer at MD Anderson and former Pharma govt; Prof. Bradley J. Monk, Director of Gynecologic Oncology on the College of Arizona School of Medication; Prof. Funda Meric-Bernstam, Chair of the Division of Investigational Most cancers Therapeutics at MD Anderson Most cancers Heart, and Dr. Jurgen Moll, former Head Molecular Oncology at Sanofi Vitry.
“We’re excited to announce this funding that helps our mission to boost the drug improvement pathway from discovery by means of commercialization,” stated Eran Seger, Co-Founder and CEO at Protai. “I’m extraordinarily pleased with our proficient staff and the achievements we’ve got made so far. We look ahead to scaling our group and its necessary work in direction of revolutionizing the drug improvement panorama.”
“Our funding in Protai highlights Maj Make investments’s rising funding within the Israeli tech ecosystem,” stated Jeppe Christian, CEO at Maj Make investments Fairness Fund. “We’re excited to companion with this distinctive staff, and we’re constructive that Protai will make an enormous leap ahead in how sufferers are handled and cured.”
About Protai
Protai empowers drug discovery and improvement with proteomic response biomarkers and synthetic intelligence to unlock new layers of organic insights and to fight advanced ailments. Protai’s platform has made a leap in fixing how drug candidates are created and validated, facilitating faster and extra superior drug discovery, particularly by means of its inside oncology pipeline. Protai is backed by mission-driven main VC funds Grove Ventures, Pitango HealthTech, and Copenhagen-based Maj Invest. with an advisory board together with world-renowned proteomics and machine studying researchers and oncology-focused pharma and medical leaders. The Tel Aviv-based firm was based by Eran Seger and Kirill Pevzner, skilled entrepreneurs and tech executives, and alumni of the elite technological unit of the Israeli intelligence corps.
Initially introduced March fifteenth, 2023
Get Contemporary Healthcare & IT Tales Delivered Day by day
Be part of hundreds of your healthcare & HealthIT friends who subscribe to our day by day e-newsletter.
[ad_2]
Source link